Lucía Gómez-Pérez

Haematologist at Hospital del Mar, Barcelona

[Talha Badar @TalhaBadarMD]

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China https://t.co/MRlggOQm7n

The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years, respectively. #HLH @BloodPortfolio

[Carlos Jiménez-Vicente @cjimenezvicente]

Excited to share our latest study in @BloodCancerJnl!

We’ve validated the AlloHCT-refined #ELN2022 risk classification for AML patients undergoing AlloHCT spotlighting the high‐risk Adv-Plus group

Thanks to all authors from @GETH_info for their help.
https://t.co/ct0AxPb7Jj

[gesmd @gesmd]

📸 #FotoDeGrupo #gesmd2025

Un encuentro con un nivel de ponencias excepcional.👏Enhorabuena a las coordinadoras, Mar Tormo y Patricia Font y a todos los ponentes.

Seguimos a las 15:00h 👉NEOPLASIAS MIELOIDES ASOCIADAS A PREDISPOSICIÓN EN LÍNEA GERMINAL Y FALLO MEDULAR @sehh_es

[Marta Salido, PhD @marta_msalido]

🎯The best of #ASH25 for MDS by the best of us @FelixLCadenas

[gesmd @gesmd]

🔝 Magistral intervención de @Santin13Valeria, de la Universidad de Florencia, sobre el manejo del #SMD de bajo riesgo y la incorporación de los nuevos #fármacos.

#gesmd #HematoEnRed @sehh_es

[Guadalupe Oñate @lupioh]

Finally out!!! Outcomes of 1000 intensively treated 18-70yrs #AML, we depict why less than 50% non-fav pts reach alloHCT in CR1, ICSA score can help orienting treatment plan at diagnosis. @hematosantpau @grupoCETLAM
@BloodCancerJnl https://t.co/TYIqDufFb9

[Moazzam Shahzad, MD @mshahzadmd]

Excited to share our first 2025 publication addressing a critical gap by exploring allo-HCT outcomes in geriatric patients, a historically underrepresented group in clinical trials due to toxicity and mortality concerns. @ASTCT_Journal @MoffittNews https://t.co/dZGg4UYGW4

[Benlazar S M A @smbenlazar]

How I treat ETP-ALL in children https://t.co/vnl8GtZ204 #leusm

[Félix L Cadenas 🇵🇸🇺🇦 @FelixLCadenas]

🍽️

[AML Hub @AML_Hub]

CONGRESS | #ASH24 | EDUCATIONAL PRESENTATION
Courtney D. DiNardo, @MDAndersonNews, discusses mutation- and MRD-informed decisions and recent advancements in the treatment of older transplant-ineligible patients with AML. She highlights that while venetoclax has markedly improved outcomes in this population, understanding its resistance mechanisms is also important for identifying patient subgroups with inferior outcomes. Treatments including IDH1, IDH2, FLT3, and menin inhibitors, alongside HMA-VEN based regimens, show promise for improving outcomes in specific patient subgroups. Follow our live feed for more updates: https://t.co/eKGIBSVEij
#AMLsm #leusm #MedicalCongress

[Nil Albiol @nilalbiol]

Look at our poster #2084 reporting the CAR-HEMATOTOX predictive results in our cohort of 58 adult patients with ALL treated at @hematoclinicbcn with #ARI0001 (var-cel). See you there at 5:30 pm (PT)!

[Miguel Argüello @miguel_argdtom]

Happy to share our comprehensive study on non-hematologic autoinmune disorders in CLL patients at #ASH24 Expansion of IL-17-F producing cells mediated by IL23 may explain lower risk of leukemic progression. Come to discuss our results at 5:30pm 🙂

[Carlos Jiménez-Vicente @cjimenezvicente]

Really happy to have presented @ASH_hematology 2024 two oral presentations on behalf of the @GETH_info and @grupoCETLAM about the AlloHCT Refined ELN 2022 Risk Classification validation and the prognostic value of MRD in AML patients treated with VenHMA @hematoclinicbcn

[Antonio Salar @ant_salar]

Proud of thesis defense of Marta Lafuente at UPF. Excellent presentation and up to date in Tumor mutational burden in follicular lymphoma. #lymphoma ⁦@ant_salar⁩

[Lucía Gómez-Pérez @ImLucia_GP]

Interesantes conclusiones sobre el impacto de la RCH en los pacientes con TE. Gran trabajo, @martaa_st 👏🏽#Hemato2024

[Lucía Gómez-Pérez @ImLucia_GP]

En sesión de tarde, la Dra. Nadal nos ha explicado la utilidad de las pruebas genéticas en la neutropenia asociada al gen ACKR1 en una población multicultural. Enhorabuena Clara! @Hemato_Mar #hemato2024

[Antonio Salar @ant_salar]

Wonderful talk of Beatriz Bellosillo PHD about molecular diagnosis of MPNs at ⁦@sehh_es⁩ @ant_salar

[Marta Salido, PhD @marta_msalido]

🎯Aspectos citologicos de las neplasias mieloides con mut TP53. #Hemato2024